Trillium Therapeutics

$17.86 0.00% ($0.00)
  • 1D
  • 1W
  • 1M
  • 1Y
  • 5Y
  • YTD

Get ready to invest

Subscribe

About Trillium Therapeutics

Trillium Therapeutics Inc. is a clinical stage immuno-oncology company. The Company develops therapies for the treatment of cancer and has preclinical programs, targeting the immunoregulatory pathways that tumor cells exploit to evade the host immune syst

Stock Analysis

last close -
1-mo return -
3-mo return -
avg daily vol. -
52-week high -
52-week low -
market cap. -
forward pe -
annual div. -
roe -
ltg forecast -
dividend yield -
annual rev. -
inst own. -
baraka

Subscribe now for daily local and international financial news

Subscribe